Fujirebio Diagnostics AB of Gothenburg at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option
Manufacturers

Fujirebio Diagnostics AB

P.O. Box 121 32, 402 42 Gothenburg
Elof Lindälvsgata 13, 414 58 Gothenburg
Sweden

Hall map

MEDICA 2019 hall map (Hall 3): stand B42

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

About us

Company details

More than 50 years' experience in pioneering IVD testing solutions 
We are a global leader in the field of high quality in vitro diagnostics (IVD) testing. At Fujirebio (our name is pronounced Fuji-Ray-Bee-o and symbolizes restoration of health) we have more than 50 years’ accumulated experience in the discovery, development, manufacturing and worldwide commercialization of robust IVD products.

Historically based in Japan with the country’s deeply rooted culture of excellence Fujirebio has over the years been shaped by the successful integration of pioneering and experienced international IVD players such as Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Our global presence includes offices in the United States, Europe, Latin America and Asia as well as a vast international distribution network.

Our IVD product lines span from specialized manual testing to fully automated routine clinical laboratory testing solutions and include both novel and routine biomarkers. We cover a variety of disease states such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism.

We have a strong and long lasting tradition for developing high quality routine and truly novel biomarkers in collaboration with the clinical community worldwide.

Established in 1950 we are today a fully owned subsidiary of Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and employ more than 1.200 people in Asia, Europe and America, including subsidiaries.

More Less